biotech

Take Heart: European Investors Regain Appetite for IPOS

Submitted by Jennifer L. Schenker on June 3, 2010

Philippe Pouletty, a French trained medical doctor and general partner at Paris-based Truffle Capital has reason to look especially cheerful these days. Carmat, a company building an entirely artificial human heart, is planning an initial public offering in June - the  third company in Pouletty's portfolio to go public in as many months. Though no one expects 2010 to look like 1999 the market for IPOs - particularly in biotech - appears to be open once again.Read more

French Biotech Firm NeoVacs Goes Public

Submitted by Jennifer L. Schenker on March 19, 2010

French biotech company Neovacs said March 19 that it will attempt to raise €20 million ($27.3 million) on the Alternext Exchange of NYSE Euronext in Paris. The developer will offer 3.9 million new shares from a capital increase or 27.46 percent of its capital, and will price the shares between €5.2 and €6.0 per share.Read more

Pioneering A New Approach To Cancer Drug Delivery

Submitted by Jennifer L. Schenker on December 7, 2009

Aura Biosciences has cobbled together a new approach to delivering cancer drugs by combining unrelated discoveries from European research institutions in the fields of virology, molecular biology, advanced chemistry, and nanotechnology. The company, which is headed by Spanish molecular biologist Elisabet de los Pinos, is one of 26 companies named as 2010 Technology Pioneers by the World Economic Forum.Read more

Syndicate content